Similar to what we found in breast cancer patients with BRCA1/2m, we found no significant association in OS in such patients harboring only BRCA1m (HR = 1.12 (95% CI = 0.96–1.13)) (Figure 3(a)), regardless of somatic or germline origin (Supplementary Figures 2(a) and 2(b), respectively), pathogenic mutational status (Supplementary Figure 2(c)), or triple-negative receptor status (Supplementary Figure 2(d)). This evidence concerns the gene BRCA1 and breast carcinoma.